AEROPERL® 300 Pharma efficiently converts lipid or oil-based APIs—such as simethicone, dimethicone, plant-based, and other hydrophobic actives—into stable, free-flowing powders. Its mesoporous structure absorbs substantial oil loads while maintaining excellent powder flow, enabling easier handling, improved dosing accuracy, and smoother downstream processing. This approach simplifies production of self-emulsifying systems, facilitates capsule filling, and supports the development of lipid-based drug delivery formats that benefit from enhanced bioavailability.
AEROPERL® 300 Pharma by Evonik
AEROPERL® 300 Pharma is a mesoporous, granulated colloidal silicone dioxide designed to improve dissolution and bioavailability while enabling robust solid dosage forms. The highly absorptive carrier silica allows to turn any kind of liquid into free-flowing powders and is also acting as desiccant for wet granulation processes
Product description & functions
AEROPERL® Pharma colloidal silicon dioxide can help with all of these formulation strategies supporting formulators to bring more API innovations to the market, improve patients well-being and generate profitable business.
The material combines all the purity and quality features of the AEROSIL® Pharma family — synthetic, amorphous silica of pharmaceutical grade, compliant with Ph. Eur. and USP/NF monographs, and manufactured under GMP guidelines.
Its granulated nature significantly reduces dusting and improves flow, even even at high liquid loadings, enabling smooth handling and direct tablet compression
AEROPERL® 300 Pharma supports multiple formulation pathways
- Carrier for lipid or liquid APIs – converts oils or solutions into solid, free-flowing powders.
- Solubility enhancer – increases dissolution rates for poorly soluble APIs (e.g. artemether, itraconazole, celecoxib).
- Inorganic solid dispersion base – stabilises APIs in amorphous form, reducing crystallisation risk.
- Micronisation carrier – prevents re-agglomeration of API crystals, increasing available surface area for dissolution
The result: higher bioavailability, simpler processing, and cleaner tablet performance.
Applications
Lipid-based formulations
Wet and dry granulation
In granulation processes, AEROPERL® 300 Pharma acts as a functional flow modifier, helping stabilise moisture-sensitive formulations and improving granule uniformity. Its high surface area and moisture-binding capacity support controlled water uptake during wet granulation and help reduce clumping during drying. In dry granulation, the material enhances flowability and reduces sticking, contributing to more consistent compaction behaviour. These benefits support robust processing and improved stability in demanding oral solid dosage form formulations.
Amorphous dispersions
The highly porous morphology of AEROPERL® 300 Pharma makes it an effective inorganic carrier for amorphous solid dispersions. Poorly water-soluble APIs, including BCS class II and IV actives, can be stabilised within the silica’s mesopores to help prevent recrystallisation. This increases available surface area for interaction with the dissolution medium and enables higher supersaturation levels. The result is improved dissolution performance, supporting enhanced oral bioavailability for challenging molecules.
Manufacturing stable tablets
AEROPERL® 300 Pharma enhances mechanical tablet strength and protects APIs from moisture-induced degradation, ensuring long-term physical and chemical stability.
-
Property
- Type
- Behaviour in water
- Specific surface area (BET)
- Tamped density
- Pore volume
- pH (4 % dispersion)
- Particle size (d50)
- Compliance
- Production
-
Unit
- -
- -
- m²/g
- g/l
- ml/g
- -
- µm
- -
- -
-
Typical value
- Granulated colloidal silicon dioxide
- Hydrophilic
- 260 – 320
- approx. 270
- 1.5 – 1.9
- 3.5 – 5.5
- 20 – 60
- Ph. Eur., USP/NF “Colloidal Silicon Dioxide”
- GMP-compliant (IPEC guidelines)
